Silence Therapeutics plc Deferred Revenue Recognized
Silence Therapeutics plc (SLNCF) reported Deferred Revenue Recognized of $600.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-03-05
- Silence Therapeutics plc contract with customer, liability, revenue recognized for fiscal 2025 was $600.00K, a 98.61% decline from fiscal 2024.
- Silence Therapeutics plc contract with customer, liability, revenue recognized for fiscal 2024 was $43.10M, a 39.48% increase from fiscal 2023.
- Silence Therapeutics plc contract with customer, liability, revenue recognized for fiscal 2023 was $30.90M.
| Period end | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|
| 2025-12-31 | $600.00K 10-K · filed 2026-03-05 |
| 2024-12-31 | $43.10M 10-K · filed 2026-03-05 |
| 2023-12-31 | $30.90M 10-K · filed 2025-02-27 |